SCHEMBL30795109

SCHEMBL30795109

CCSc1nc(N2CCOCC2)cc(C)c1C(=O)NCCCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPEPLD Q6IQ20 12/20 0.53
LMNA P02545 1/20 0.47
THRB P10828 1/20 0.47
TP53 P04637 1/20 0.46
MAPK1 P28482 1/20 0.46
TSHR P16473 2/20 0.45
TAAR1 Q96RJ0 1/20 0.45
RAB9A P51151 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
GAA P10253 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PKM P14618 1/20 0.44
CRHBP P24387 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2128423 1.00 NAPEPLD (0.53) NAPEPLDLMNATHRBTP53MAPK1
SCHEMBL2128718 0.95 LMNA (0.53) NAPEPLDLMNATHRBTP53TSHR
SCHEMBL30796087 0.95 LMNA (0.53) NAPEPLDLMNATHRBTP53TSHR
SCHEMBL2129221 0.92 NAPEPLD (0.44) NAPEPLDLMNATHRBRAB9AKDM4E
SCHEMBL30796513 0.92 NAPEPLD (0.44) NAPEPLDLMNATHRBRAB9AKDM4E
SCHEMBL30794891 0.91 NAMPT (0.46) NAPEPLDRAB9AKDM4ENPC1ALDH1A1
SCHEMBL2129273 0.91 NAMPT (0.46) NAPEPLDRAB9AKDM4ENPC1ALDH1A1
SCHEMBL2128542 0.91 NAPEPLD (0.46) NAPEPLDRAB9AKDM4ENPC1ALDH1A1
SCHEMBL2130149 0.91 NAPEPLD (0.44) NAPEPLDRAB9AKDM4ENPC1ALDH1A1
SCHEMBL30795105 0.91 NAPEPLD (0.46) NAPEPLDRAB9AKDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed